Literature DB >> 15499117

The PROGRESS trial three years later: time for more action, less distraction.

Stephen Macmahon1, Bruce Neal, Anthony Rodgers, John Chalmers.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15499117      PMCID： PMC524115          DOI： 10.1136/bmj.329.7472.970

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  The PROGRESS trial: questions about the effectiveness of angiotensin converting enzyme inhibitors. Perindopril pROtection aGainst REcurrent Stroke Study.

Authors:  Bruce M Psaty; Noel S Weiss; Curt D Furberg
Journal:  Am J Hypertens       Date:  2002-05       Impact factor: 2.689

2.  Secondary prevention for stroke and transient ischaemic attacks.

Authors:  Keith W Muir
Journal:  BMJ       Date:  2004-02-07

3.  The PROGRESS trial three years later: time for a balanced report of effectiveness.

Authors:  Richard Wennberg; Camilla Zimmermann
Journal:  BMJ       Date:  2004-10-23

4.  Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group.

Authors:  A Rodgers; S MacMahon; G Gamble; J Slattery; P Sandercock; C Warlow
Journal:  BMJ       Date:  1996-07-20

5.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

Authors: 
Journal:  Lancet       Date:  2001-09-29       Impact factor: 79.321

6.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease.

Authors: 
Journal:  Eur Heart J       Date:  2003-03       Impact factor: 29.983

9.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Authors:  Fiona Turnbull
Journal:  Lancet       Date:  2003-11-08       Impact factor: 79.321

10.  Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial.

Authors:  M Fransen; C Anderson; J Chalmers; N Chapman; S Davis; S MacMahon; B Neal; R Sega; A Terent; C Tzourio; M Woodward
Journal:  Stroke       Date:  2003-09-04       Impact factor: 7.914
  10 in total
  5 in total

1.  Understanding and managing hypertension in an African sub-district: a multidisciplinary approach.

Authors:  Margaret Thorogood; Myles D Connor; Gillian Lewando Hundt; Stephen M Tollman
Journal:  Scand J Public Health Suppl       Date:  2007-08       Impact factor: 3.021

2.  ASCOT: a tale of two treatment regimens: odds are that it's hype.

Authors:  Martin G Duerden
Journal:  BMJ       Date:  2005-10-29

3.  Perindopril monotherapy and PROGRESS in Europe.

Authors:  Richard Wennberg; Camilla Zimmermann
Journal:  BMJ       Date:  2005-07-23

Review 4.  Progress in the identification of stroke-related genes: emerging new possibilities to develop concepts in stroke therapy.

Authors:  Andrea Lippoldt; Andreas Reichel; Ursula Moenning
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Delapril plus indapamide: a review of the combination in the treatment of hypertension.

Authors:  Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.